Leukemic stem cells: identification and clinical application.
about
CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia.Update of ALDH as a Potential Biomarker and Therapeutic Target for AML.CD34-negative hematopoietic stem cells show distinct expression profiles of homing molecules that limit engraftment in mice and sheep.
P2860
Leukemic stem cells: identification and clinical application.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Leukemic stem cells: identification and clinical application.
@en
Leukemic stem cells: identification and clinical application.
@nl
type
label
Leukemic stem cells: identification and clinical application.
@en
Leukemic stem cells: identification and clinical application.
@nl
prefLabel
Leukemic stem cells: identification and clinical application.
@en
Leukemic stem cells: identification and clinical application.
@nl
P2093
P2860
P1476
Leukemic stem cells: identification and clinical application.
@en
P2093
Diana Hanekamp
Gerrit Jan Schuurhuis
Jacqueline Cloos
P2860
P2888
P304
P356
10.1007/S12185-017-2221-5
P577
2017-03-29T00:00:00Z